Inve US ▾
RGRGEN

Repligen (RGEN) Q4 FY25 earnings call: guidance and Q&A

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 24, 2026

Source: earnings call transcript

Executive summary

Repligen Q4 FY25 — Robust Organic Growth and Margin Expansion

Repligen concluded FY25 with strong organic growth and margin expansion, driven by portfolio diversity and strategic execution. The company issued prudent FY26 guidance, balancing a strengthening macro backdrop with near-term uncertainties around FDA policy and biopharma CapEx decisions, while prioritizing continued investment and M&A. Innovation and operational fitness remain key strategic pillars for future growth.

Highlights

5

  • Q4 revenue of $198 million, translating to 14% organic growth.

  • Full-year 2025 organic growth of 14%, exceeding the high end of initial guidance.

  • Proteins and Process Analytics grew over 30% in Q4, with Chromatography over 25%.

  • Adjusted operating margin expanded by 90 basis points to 13.8% in FY25 (240 bps excluding M&A and FX).

  • Cash and marketable securities reached $768 million, up $90 million sequentially.

Concerns

5

  • 2-point headwind from a gene therapy platform impacting 2026 organic revenue guidance.

  • CDMO Q4 revenue grew low single digits year-over-year due to a tough comparison.

  • Muted demand for capital equipment in 2025, though sales were flat year-over-year.

  • Tariff surcharges expected to have a slightly higher impact on revenue and margin in 2026 (50 bps headwind on gross margin).

  • Lower interest income of $2 million in Q4 FY25 due to declining interest rates.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Revenue
$810 million to $840 million
high materiality
High
Full-year 2026 Organic Revenue Growth
9% to 13%
high materiality
High
Full-year 2026 Adjusted Gross Margin
53.6% to 54.1%
high materiality
High
Full-year 2026 Adjusted Income from Operations
$122 million to $130 million
high materiality
High
Full-year 2026 Adjusted Operating Margin Expansion
150 basis points
high materiality
High
Full-year 2026 Adjusted Effective Tax Rate
22% to 23%
medium materiality
High
Full-year 2026 Adjusted Fully Diluted EPS
$1.93 and $2.01
high materiality
High
Full-year 2026 Filtration Revenue Growth
Low double digits
medium materiality
High
Full-year 2026 Chromatography Revenue Growth
Low double digits
medium materiality
High
Full-year 2026 Proteins Revenue Growth
Low double digits
medium materiality
High
Full-year 2026 Analytics Revenue Growth
Greater than 20%
medium materiality
High
Full-year 2026 Revenue Seasonality
~48% in the first half
low materiality
Medium
Q1 2026 Revenue
Low single digits sequential decline
medium materiality
High
Full-year 2026 CapEx Spend
Approximately 3% to 4% of 2026 revenue
low materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
North America
Q4 growth driven by Proteins, ATF, and Fluid Management. Full-year growth was approximately 16%.
—mid-teens——
EMEA
Q4 growth driven by Proteins, Chromatography, and Analytics. Full-year growth was approximately 16%.
—more than 20%——
Asia Pacific
Q4 growth driven by Chromatography and Analytics. Full-year growth was 19%.
—high teens——

Product announcements

ProductTypeDetails
SoloVPE PLUSlaunch
ProConnex MixOnelaunch
AVIPure Resinslaunch
New Catalog Resins (Proteins)roadmap
Mid-IR Technologyroadmap

Deals & partnerships

908 Devices Acquisition of 908 Devices' bioprocessing portfolio.

Acquired in March 2025, now part of Repligen's rebranded PATsmart portfolio. Cross-trained and merged upstream and downstream analytics teams, resulting in a growing funnel of opportunities.

Tantti Integration of Tantti.

Made progress on the integration of Tantti.

Novasign Strategic partnership and minority investment to develop and integrate machine learning and modeling workflow into Repligen filtration systems.

Announced in July 2025. Investment in Novasign aims to scale and expand their operations, furthering Repligen's digitization efforts and highlighting minority investments as a capital allocation avenue.

Risks & headwinds

Gene Therapy Platform Headwind FY26

2-point headwind on 2026 organic revenue growth; 3-point headwind for Filtration franchise.

FDA Policy Uncertainty 2026

Near-term uncertainty

Biopharma Strategic Response to MFN 2026

Near-term uncertainty, potential for delay on specific CapEx spending decisions.

Tariff Surcharges FY26

Slightly higher impact on revenue and margin than 2025; approximately 50 basis points headwind on gross margin.

Mitigation:Evaluating implications of recent Supreme Court ruling; administration's alternatives to current regime expected to be a push or slightly better.

Muted Capital Equipment Demand 2025-2026

CapEx sales flat YoY in 2025, market down significantly (high teens). Expecting somewhat flat sales for downstream systems in 2026.

Mitigation:Hoping for better macro environment and acceleration of onshoring projects towards mid-year with potential grants.

Lower Interest Income Q4 FY25, FY26

$2 million lower in Q4 FY25; assumed $18 million for FY26 (slightly lower than 2025).

What to watch in Q1 FY26

Conversion of high-probability funnel opportunities

2026
Current highest level ever
Target Translation into orders and sales

Why it matters

Indicates underlying demand strength and potential for upside to guidance.

I mean we have a very strong funnel of opportunity. And as you know, we're tracking that very specifically, particularly the funnel with high probability above 50%. This is at the highest level ever and significantly higher than a year ago.

Find out whether RGEN delivers this. Inve re-checks your case every morning.

Q&A highlights

Seeking clarification on the factors influencing the low and high ends of the FY26 guidance, particularly regarding FDA policy, MFN impact, funnel opportunities, and tariffs.

Tariffs have a minimal impact (<1% of sales), and onshoring opportunities are deferred to 2027. The high-probability funnel is at an all-time high. Key uncertainties include biopharma's digestion of MFN deals potentially delaying CapEx decisions and the slow pace of FDA approvals for biologics in early 2026, which could shift guidance.

“I mean we have a very strong funnel of opportunity. And as you know, we're tracking that very specifically, particularly the funnel with high probability above 50%. This is at the highest level ever and significantly higher than a year ago.”

asked by Matthew Larew · answered by Olivier Loeillot

2 min read 6 chapters

Detailed narrative

Strong FY25 Performance and Strategic Execution

Repligen delivered a robust 16% reported and organic non-COVID growth in FY25, surpassing the high end of its initial guidance. This performance was attributed to broad momentum across its diverse portfolio, customer base, and geographies. The company successfully executed on five strategic priorities, including accelerating growth, driving operating leverage, fostering innovation, pursuing M&A, and enhancing operational fitness, setting a strong foundation for future expansion.

Portfolio Diversity and Growth Drivers

The company's diverse product portfolio proved to be a key strength, with Proteins and Process Analytics franchises achieving over 30% growth in Q4, and Chromatography growing over 25%. Consumables were a significant growth driver in Q4, increasing by over 20%. The SoloVPE PLUS upgrade cycle is anticipated to be a multi-year opportunity, and new resins developed for the new modality market are gaining considerable traction, contributing to sustained growth.

Margin Expansion and Strategic Investments

Repligen expanded its adjusted operating margin by 90 basis points to 13.8% in FY25, or 240 basis points excluding the impact of M&A and foreign exchange. This margin expansion was achieved while making critical investments in legal, finance, IT leadership, AI, and infrastructure. For FY26, the company targets an additional 150 basis points of operating margin expansion, balancing profitability with necessary investments for future scalability.

M&A and Capital Allocation Strategy

In FY25, Repligen expanded its portfolio through the acquisition of 908 Devices' bioprocessing assets and a strategic minority investment in Novasign. M&A remains the top capital allocation priority for FY26, with a focus on acquiring differentiated technologies that address customer pain points and offer financial accretion. The company maintains a healthy balance sheet with $768 million in cash and marketable securities to support these strategic initiatives.

Regional Performance and China Outlook

North America and Europe each grew approximately 16% in FY25, while Asia Pacific saw 19% growth. China, despite representing a smaller portion of total revenue (2-3% in FY25), showed positive momentum with two consecutive quarters of top-line growth and strong Q4 orders. Repligen is optimistic about China returning to significant growth in FY26 and beyond, driven by increased investment and strategic partnerships in the region.

Services Growth Opportunity

Services currently account for approximately 6% of Repligen's total sales, significantly below industry benchmarks. The company identifies this as a substantial growth opportunity, aiming to reach 10% of total sales in the coming years. Efforts are focused on increasing attachment rates for larger-scale equipment, leveraging the high success seen in the analytics franchise, and investing in dedicated commercial resources for service expansion.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.